Rosetta Genomics' H1 2012 Revenues Slide 14 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Rosetta Genomics' first-half 2012 revenues saw a 14 percent drop year over year, the company reported after the close of the market on Friday.

During the first six months of the year, the Israel-based molecular diagnostics firm reported $51,000 in revenues, down from $59,000 a year ago.

Its R&D expenses were sliced to $740,000 from $1.9 million in H1 2011, while SG&A costs were lowered to $2.5 million $2.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.